Saturn V Capital Management LLC Morphic Holding, Inc. Transaction History

Saturn V Capital Management LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$26.12 - $34.07 $991,828 - $1.29 Million	-37,972 Reduced 44.34%	47,660 $1.62 Billion
Q1 2024 May 15, 2024	SELL	$26.64 - $40.31 $3.38 Million - $5.11 Million	-126,711 Reduced 59.67%	85,632 $3.01 Billion
Q4 2023 Feb 14, 2024	BUY	$19.95 - $31.0 $1.51 Million - $2.34 Million	75,600 Added 55.29%	212,343 $6.13 Billion
Q3 2023 Nov 14, 2023	SELL	$21.33 - $59.42 $333,110 - $927,962	-15,617 Reduced 10.25%	136,743 $3.13 Billion
Q2 2023 Aug 14, 2023	SELL	$34.33 - $62.11 $3.24 Million - $5.85 Million	-94,256 Reduced 38.22%	152,360 $8.73 Billion
Q1 2023 May 15, 2023	SELL	$26.01 - $48.69 $603,718 - $1.13 Million	-23,211 Reduced 8.6%	246,616 $9.28 Billion
Q4 2022 Feb 09, 2023	BUY	$24.14 - $30.37 $6.51 Million - $8.19 Million	269,827 New	269,827 $7.37 Billion

4.7M

Ticker MORF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,477,100
Market Cap $2.19B
Description
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical ...

Get notified when there are updates to the investment portfolio of Saturn V Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Saturn V Capital Management LLC with notifications on news.